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Defining the characteristics of leukemia stem cells is critical in order to better understand both the genesis of leukemic disease 
and strategies by which such cells may be eradicated. In this issue of Cancer Cell, Somervaille and Cleary describe studies in 
which the properties of malignant stem cells are elucidated in a mouse model of leukemia induced by expression of the MLL-
AF9 translocation. Biological features of leukemia stem cells in this system challenge previous thinking in several ways and 
suggest an unexpected degree of heterogeneity among stem cells in various forms of leukemia.In 1994, a landmark study by Lapidot et al. 
first described the immunophenotype and 
isolation of stem cells from primary human 
acute myeloid leukemia (AML) specimens 
(Lapidot et al., 1994). From that study and 
several others over the next 6–7 years, a 
seemingly clear picture emerged—AML 
stem cells (AML-SCs) could be identified 
by a specific set of immunophenotypic 
markers. While many of these markers 
were shared with normal hematopoietic 
stem cells (HSCs), some differed as well. 
Nonetheless, a profile emerged that was 
apparently shared among the majority of 
AML-SCs and seemed to indicate that such 
cells are closely analogous to HSCs. Indeed, 
it was easy to imagine that oncogenic sub-
version of a normal stem cell would be the 
most logical manner in which an leukemia 
stem cell might arise.
Following the initial human studies, a 
more recent series of reports has exploited 
the power of mouse molecular genetics to 
model the stem cell biology of myeloid leu-
kemia. Most of these studies have employed 
retroviral vectors to introduce specific onco-
genic mutations into primitive hematopoi-
etic cells. Experiments of this nature have 
shown that primary AML can be readily 
generated in the mouse, with pathological 
features that closely mimic human disease. 
As anticipated from the earlier human stud-
ies, expression of appropriate oncogenes 
in mouse HSCs leads to the formation of 
de novo AML (Huntly and Gilliland, 2005). 
Intriguingly, two recent reports indicate that 
expression of some oncogenes in more 
differentiated cell types is also sufficient 
to induce AML (Cozzio et al., 2003; Huntly 
et al., 2004). Specifically, those studies 
showed that expression of the MLL-ENL or 
MOZ-TIF2 translocations in either common 
myeloid progenitors (CMPs) or granulocyte-
macrophage progenitors (GMPs) was able 
to cause AML, albeit at a lower efficiency 
than HSCs. Thus, the precedent has been 
formally established that the originating 
normal cell for AML in the mouse need not 
necessarily be a HSC.
In the current issue of Cancer Cell, a 
study by Somervaille and Cleary (2006) 
cancer cell 10, september 2006 © 2006 elsnow takes the important next step of defin-
ing the immunophenotype and properties 
of leukemia stem cells in a mouse model of 
AML. Using retroviral transduction of normal 
hematopoietic cells with the MLL-AF9 trans-
location, the authors observe the expected 
development of AML and perform experi-
ments to identify the subset of cells that can 
be functionally defined as AML-SCs. As is 
done for analyses of normal stem cells, 
establishing such functionality is accom-
plished by transplanting a small number of 
putative stem cells into secondary recipient 
animals and asking for regeneration of the 
overall (hierarchically organized) population. 
Surprisingly, their findings indicate that most 
AML-SCs are not found among the more 
phenotypically primitive cell types, but rather 
express both the Mac1 and Gr1 antigens, 
markers typically found on more mature 
myeloid cells. Interestingly, the majority of 
AML-SCs in this system also express the 
stem cell antigen c-kit, thereby indicating 
at least some primitive features. A second 
surprising observation is the relatively high 
frequency of AML-SCs in this model, esti-
mated at approximately 25% of the overall 
leukemic population, much higher than the 
frequency of leukemia-initiating cells in other 
systems, which ranges from approximately 
1.0% to approximately 0.0001%. The abun-evier inc. dance of AML-SCs was established by first 
plating leukemia cells in semisolid medium 
and then isolating and transplanting individ-
ual colonies arising from the in vitro cultures. 
These experiments showed that 25%–30% 
of leukemia cells were able to generate col-
onies in vitro and that all of those colonies 
were able to induce AML upon transplanta-
tion into recipient mice. Thus, the overall fre-
quency of AML-SCs appeared to correlate 
directly with the frequency of in vitro colony-
forming cells. Notably, when conventional 
limiting-dilution studies were performed by 
directly transplanting graded doses of leu-
kemia cells into secondary recipients, the 
frequency of AML-SCs was much lower (1 
in 121). The authors conclude that the rela-
tive homing efficiency of AML-SCs in their 
model is low and suggest that this may be a 
feature of other tumor stem cells.
Another very recent report has also 
employed retroviral gene transfer of the 
MLL-AF9 as a means to characterize leu-
kemia stem cells (Krivtsov et al., 2006). 
Krivtsov et al. performed studies in which 
highly purified populations of normal GMPs 
were transduced to express MLL-AF9. 
Transplantation of such cells into recipient 
mice yielded AML in which a phenotypically 
defined leukemic GMP population showed 
the functional characteristics of AML-SCs. Figure 1. Hypothetical parameters affecting the genesis of Aml stem cells
initial mutations occur at the level of normal stem cells (Hsc) or myeloid progenitors (cmp or Gmp), 
giving rise to preleukemic populations (denoted by asterisk). subsequent development of preleukemic 
cells may be arrested at the stage of the original mutation or progress partially to the various popula-
tions shown. Finally, after some interval of growth, additional mutations occur to generate the fully 
transformed Aml stem cell.253
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conflict with the work of Somervaille and 
Cleary, in that the immunophenotype of 
AML-SCs is quite different. However, it is 
actually not possible to directly compare 
the reports due to substantial differences 
in methodology. The two groups employed 
different populations of normal cells for the 
original transduction with MLL-AF9, differ-
ent strategies for functional characteriza-
tion of AML-SCs, and different methods to 
estimate the frequency of AML-SCs. Taken 
together, these factors could certainly lead 
to varying interpretations and conclusions, 
despite the common feature of studying 
MLL-AF9-induced leukemias.
Considered more broadly, the reports of 
Somervaille and Cleary (2006) and Krivtsov 
et al. (2006) serve to emphasize an intrigu-
ing point—the basic properties of AML-SCs 
may be relatively heterogeneous and may 
vary as a function of genetics and develop-
mental origin. Figure 1 illustrates some of 
the hypothetical steps leading to the gen-
eration of AML-SCs. When one considers 
the specific type of initial mutation (step 1), 
the originating target cell (step 2), subse-
quent differentiation or lack thereof (step 3), 
and the types of subsequent mutations that 
may occur (step 4), the number of possible 
permutations in the genesis of AML-SCs is 
quite large. Furthermore, given the inher-
ently unstable genome of most malignant 
cells and possible changes evoked by 
challenge with various drug therapies, the 
resulting phenotype of human AML-SCs is 
potentially even more complex.
Given the issues above, several ques-
tions regarding the evolution and properties 
of AML-SCs should be considered. Perhaps 254 
The PI3K/AKT kinase pathway is a cen-
tral regulator of cell metabolism, prolif-
eration, and survival and is dysregulated 
by oncogenic events in a substantial 
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AKT, a key regulator of cell proliferation a
oncogenic and required for tumorigenesis
tion by other oncogenes and which of its t
Cell, Skeen et al. show that AKT is requir
Moreover, the effects of AKT are mediated
will be useful treatments for many cancersmost importantly, while the elegant studies 
in mouse models have indicated differing 
paths by which leukemia stem cells may 
arise, are any of these scenarios prevalent 
in primary human disease? To date, the only 
direct studies indicating a GMP-like origin 
for an acute form of myeloid disease is the 
report by Jamieson et. al. that describes 
studies of blast crisis CML (chronic myeloid 
leukemia) (Jamieson et al., 2004). CML is 
unique among myeloid leukemias in that it 
displays an overt and well-defined pathology 
at each stage of progression, and thereby 
permits the isolation and analysis of stem 
cells from early (chronic) and late (blast 
crisis) forms of disease. However, aside 
from CML, in five of the other eight major 
subtypes of AML (designated as FAB types 
M0, M1, M2, M4, and M5), the only AML-
SCs characterized to date are both rare and 
phenotypically similar to HSCs (Bonnet and 
Dick, 1997). Therefore, while the data from 
mouse models are compelling, their direct 
relevance to human disease remains a 
largely unanswered question. Indeed, from 
a genetic perspective, evidence suggests 
that transformation of human cells is more 
complex than murine cells (Rangarajan and 
Weinberg, 2003); thus, findings from one 
species should be validated in the other. 
Going forward, it will be important to iden-
tify and isolate human counterparts to the 
entities described thus far from murine stud-
ies. Such efforts may come from the analy-
sis of primary specimens, as described by 
Jamieson et al., or may also derive from the 
generation of better experimental models. In 
this regard, the studies cited above using 
gene transfer into normal murine progeni-
tor cells have likely established an important fraction of tumors. Constitutive activa-
tion of growth factor receptors, mutation 
of PI3K, and inactivation of the PTEN 
phosphatase cause the activation of PI3K 
all mTOR?
nd survival, is commonly dysregulated in 
 in PTEN-deficient animals. However, the im
argets are necessary for this process are p
ed for transformation by mutant H-Ras an
 predominantly or solely via mTORC1. Thi
.precedent for future efforts using primary 
human cells.
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